(Q54680146)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

title

Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

author name string

Hiroyuki Yamaguchi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Yoichi Nakamura

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Mineyo Takasu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Nanae Tomonaga

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Hirofumi Nakano

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Seiji Doi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Katsumi Nakatomi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Seiji Nagashima

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Hiroshi Takatani

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Minoru Fukuda

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Tomayoshi Hayashi

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Kazuhiro Tsukamoto

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Shigeru Kohno

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

publication date

17 April 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

31 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

volume

67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

page(s)

331-338

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20401612%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00280-010-1325-x

31 January 2020

exact match

0 references

cites work

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

EGFR mutation is specific for terminal respiratory unit type adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

Antisense inhibition of epidermal growth factor receptor decreases expression of human surfactant protein A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

Surfactant proteins SP-A and SP-D: structure, function and receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

Surfactant protein C expression in urethane-induced murine pulmonary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/extracellular signal-regulated kinase cascade and Sp1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1325-X